After considering the feedback from consultation, the Appraisal Committee has prepared a Final Evaluation Determination (FED) on Burosumab for treating X-linked hypophosphataemia [ID1151] and submitted it to the Institute.
The FED has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FED has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FED may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, Wednesday 19 September 2018.
This page was last updated: 05 September 2018